Pmv Pharmaceuticals Inc (PMVP)

$1.48

-0.01

(-0.67%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $1.46
    $1.51
    $1.48
    downward going graph

    1.35%

    Downside

    Day's Volatility :3.31%

    Upside

    1.99%

    downward going graph
  • $1.18
    $6.66
    $1.48
    downward going graph

    20.61%

    Downside

    52 Weeks Volatility :82.36%

    Upside

    77.78%

    downward going graph

Returns

PeriodPmv Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-4.49%
7.5%
0.0%
6 Months
-12.35%
6.9%
0.0%
1 Year
-75.13%
20.9%
0.0%
3 Years
-94.84%
21.0%
-21.1%

Highlights

Market Capitalization
77.3M
Book Value
$4.16
Earnings Per Share (EPS)
-0.96
Wall Street Target Price
8.2
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-19.88%
Return On Equity TTM
-22.62%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-74.8M
Diluted Eps TTM
-0.96
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.05
EPS Estimate Next Year
-1.65
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Pmv Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 454.05%

Current $1.48
Target $8.20

Technicals Summary

Sell

Neutral

Buy

Pmv Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pmv Pharmaceuticals Inc
Pmv Pharmaceuticals Inc
-5.7%
-12.35%
-75.13%
-94.84%
-96.03%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.06%
10.55%
30.05%
89.27%
274.48%
Novo Nordisk A/s
Novo Nordisk A/s
-12.62%
-6.24%
35.65%
145.66%
372.59%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.37%
82.34%
59.06%
41.03%
258.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.23%
13.76%
34.75%
162.16%
172.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pmv Pharmaceuticals Inc
Pmv Pharmaceuticals Inc
NA
NA
NA
-1.05
-0.23
-0.2
NA
4.16
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.85
27.85
1.43
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.39
40.39
1.82
3.45
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pmv Pharmaceuticals Inc
Pmv Pharmaceuticals Inc
Buy
$77.3M
-96.03%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.9B
274.48%
27.85
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$531.4B
372.59%
40.39
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.3B
258.58%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.0B
172.77%
32.84
-4.74%

Insights on Pmv Pharmaceuticals Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 134.2%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 137.8%

Institutional Holdings

  • Orbimed Advisors, LLC

    12.57%

  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    5.44%

  • Sio Capital Management, LLC

    5.26%

  • Euclidean Capital LLC

    5.10%

  • Alkeon Capital Management, LLC

    4.55%

  • Vanguard Group Inc

    4.43%

Company Information

pmv pharmaceuticals, inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. its lead product candidate is pc14586, a small molecule that corrects and restores p53 function. the company also develops product candidates for p53 r273h hotspot mutation and other p53 hotspot mutations. pmv pharmaceuticals, inc. was formerly known as pj pharmaceuticals, inc. and changed to in july 2013. the company was founded in 2013 and is headquartered in cranbury, new jersey.

Organization
Pmv Pharmaceuticals Inc
Employees
63
CEO
Dr. David H. Mack Ph.D.
Industry
Commercial Services

Discover More

FAQs